Development and validation of quality of life instruments for chronic diseases -- chronic gastritis version 2 (QLICD-CG V2.0)

Development and validation of quality of life instruments for chronic diseases -- chronic gastritis version 2 (QLICD-CG V2.0

Data from: Development and validation of quality of life instruments for chronic diseases—chronic gastritis version 2 (QLICD-CG V2.0)

Quality of life is an important outcome indicator to evaluate whether treatment is successful or not. Chronic gastritis leads to ongoing deterioration of subjectively perceived quality of life. There are several generic measures, but they are not developed particularly to assess chronic gastritis problems. The Quality of Life Instruments for Chronic Diseases—Chronic Gastritis (QLICD-CG V2.0) questionnaire is a 39-item, multi-dimensional, self-report instrument to assess chronic gastritis patients’ perception of their health related quality of life in four domains. The instrument was developed in China. The current study aimed to evaluate the psychometric properties of the QLICD-CG V2.0. 194 patients with chronic gastritis were enrolled from 4 hospitals in China. The QLICD-CG V2.0 was administered to patients by trained research assistants. In addition, their demographic characteristics were also recorded. The psychometric testing included construct validity, convergent validity, discriminant validity, test-retest, and responsiveness. The results showed good internal consistency and acceptable floor and ceiling effects (Cronbach’s alpha range from 0.80 to 0.93). CFA showed that the instrument structure has a reasonable fitness (RMSEA = 0.063, 95%CI = [0.057 0.079], CFI = 0.93, GFI = 0.95, SRMR = 0.028). The convergent validity was considered appropriate, with 38 of the 39 items correlated stronger with their assigned scale than a competing scale, except for GPS1. Known groups comparisons showed that the QLICD-CG V2.0 discriminated well between subgroups on the basis of gender, marriage status, and economy status, thus providing evidence of discriminative validity. Convergent validity testing revealed that the QLICD-CG V2.0 domain scores correlated significantly with SF-36 dimension scores, which ranged from 0.21 to 0.58. Test-retest coefficients were satisfactory. A majority of intraclass correlation coefficients were above 0.70, except the psychological domain (0.60) and the items of social support/security (0.61). Responsiveness was tested on 157 patients. Significant differences were found on all QLICD-CG V2.0 domains, between baseline responses and after a treatment, except for the items of appetite and sleep. Robust sensitivity to change was observed. The QLICD-CG V2.0 appears to be a valid and reliable instrument to measure QOL in chronic gastritis patients. Scores were reproducible

Development and validation of quality of life instruments for chronic diseases-Chronic gastritis version 2 (QLICD-CG V2.0).

Quality of life is an important outcome indicator to evaluate whether treatment is successful or not. Chronic gastritis leads to ongoing deterioration of subjectively perceived quality of life. There are several generic measures, but they are not developed particularly to assess chronic gastritis problems. The Quality of Life Instruments for Chronic Diseases-Chronic Gastritis (QLICD-CG V2.0) questionnaire is a 39-item, multi-dimensional, self-report instrument to assess chronic gastritis patients' perception of their health related quality of life in four domains. The instrument was developed in China. The current study aimed to evaluate the psychometric properties of the QLICD-CG V2.0. 194 patients with chronic gastritis were enrolled from 4 hospitals in China. The QLICD-CG V2.0 was administered to patients by trained research assistants. In addition, their demographic characteristics were also recorded. The psychometric testing included construct validity, convergent validity, discriminant validity, test-retest, and responsiveness. The results showed good internal consistency and acceptable floor and ceiling effects (Cronbach's alpha range from 0.80 to 0.93). CFA showed that the instrument structure has a reasonable fitness (RMSEA = 0.063, 95%CI = [0.057 0.079], CFI = 0.93, GFI = 0.95, SRMR = 0.028). The convergent validity was considered appropriate, with 38 of the 39 items correlated stronger with their assigned scale than a competing scale, except for GPS1. Known groups comparisons showed that the QLICD-CG V2.0 discriminated well between subgroups on the basis of gender, marriage status, and economy status, thus providing evidence of discriminative validity. Convergent validity testing revealed that the QLICD-CG V2.0 domain scores correlated significantly with SF-36 dimension scores, which ranged from 0.21 to 0.58. Test-retest coefficients were satisfactory. A majority of intraclass correlation coefficients were above 0.70, except the psychological domain (0.60) and the items of social support/security (0.61). Responsiveness was tested on 157 patients. Significant differences were found on all QLICD-CG V2.0 domains, between baseline responses and after a treatment, except for the items of appetite and sleep. Robust sensitivity to change was observed. The QLICD-CG V2.0 appears to be a valid and reliable instrument to measure QOL in chronic gastritis patients. Scores were reproducible

Analysis of the Measurement Characteristics of Inflammatory Bowel Disease Patient-reported Outcomes Measurement Scale

Background The reported outcome level of patients with inflammatory bowel disease (IBD) has received attention. There are few mature outcome scales with Chinese cultural characteristics for patients with IBD, and the developed scales need strict evaluation. Objective To analyze and evaluate the measurement properties of the Inflammatory Bowel Disease Patient-Reported Outcome Measurement Scale〔PROISCD-IBD (V1.0) 〕, to provide basis for scientific evaluation of reported outcomes in patients with IBD. Methods From October 2020 to January 2022, PROISCD-IBD (V1.0) was used to detect 274 IBD patients who were treated in the Outpatient and Inpatient Departments of Gastroenterology in the First Affiliated Hospital of Kunming Medical University and the Affiliated Hospital of Guangdong Medical University. PROISCD IBD (V1.0) consisted of 1 commonality module and 1 IBD specific module (TIBD) . The commonality module had 30 items, which were divided into 4 domains of physical health (PHD) , mental health (MHD) , social health (SHD) , and spiritual/belief health (SBD) . TIBD covered four aspects of digestive system symptoms (DSS) , extraintestinal symptom (EXS) , special psychological symptoms (SPP) , and treatment side effects (TSE) . Cronbach's α coefficient and split-half coefficient were used to test the reliability. Correlation coefficient method, exploratory factor analysis and structural equation model were used to analyze the structural validity. Clinical validity of each domain was analyzed using t test. Results The Cronbach's α coefficients of PHD, MHD, SHD, SBD and TIBD of PROISCD-IBD (V1.0) were 0.732, 0.838, 0.781, 0.673 and 0.884, respectively. Cronbach's α coefficient of total scale was 0.932. The half-score coefficients of PHD, MHD, SHD, SBD and TIBD were 0.669, 0.859, 0.610, 0.494 and 0.795, respectively, and the half-score reliability of the total scale was 0.879. Correlation analysis showed that the phase coefficients of PHD, MHD, SHD and SBD scores and commonality module score were all >0.6 (P<0.05) . Three principal components were extracted from exploratory factor analysis, and the cumulative variance contribution rate was 58.05%. Structural equation model showed that χ2/df=2.568, root-mean-square error of approximation (RMSEA) =0.076, normed fit index (NFI) =0.677, non-normed fit index (NNFI) =0.774, comparative fit index (CFI) =0.772, incremental fit index (IFI) =0.774, SRMR=0.103 1. IBD patients were divided into active stage (n=90) and remission stage (n=184) according to clinical stages. The total scores of various domains, common modules, TIBD and scale in remission stage were higher than those in active stage (P<0.05) . Conclusion PROISCD-IBD (V1.0) has good reliability and validity for reporting outcome measures in patients with IBD

Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease

Abstract Background/aims Nonobese metabolic dysfunction-associated fatty liver disease (MAFLD) is paradoxically associated with improved metabolic and pathological features at diagnosis but similar cardiovascular diseases (CVD) prognosis to obese MAFLD. We aimed to utilize the metabolomics to identify the potential metabolite profiles accounting for this phenomenon. Methods This prospective multicenter cross-sectional study was conducted in China enrolling derivation and validation cohorts. Liquid chromatography coupled with mass spectrometry and gas chromatography-mass spectrometry were applied to perform a metabolomics measurement. Results The study involved 120 MAFLD patients and 60 non-MAFLD controls in the derivation cohort. Controls were divided into two groups according to the presence of carotid atherosclerosis (CAS). The MAFLD group was further divided into nonobese MAFLD with/without CAS groups and obese MAFLD with/without CAS groups. Fifty-six metabolites were statistically significant for discriminating the six groups. Among the top 10 metabolites related to CAS in nonobese MAFLD, only phosphatidylethanolamine (PE 20:2/16:0), phosphatidylglycerol (PG 18:0/20:4) and de novo lipogenesis (16:0/18:2n-6) achieved significant areas under the ROC curve (AUCs, 0.67, p = 0.03; 0.79, p = 0.02; 0.63, p = 0.03, respectively). The combination of these three metabolites and liver stiffness achieved a significantly higher AUC (0.92, p < 0.01). In obese MAFLD patients, cystine was found to be significant with an AUC of 0.69 (p = 0.015), followed by sphingomyelin (SM 16:1/18:1) (0.71, p = 0.004) and de novo lipogenesis (16:0/18:2n-6) (0.73, p = 0.004). The combination of these three metabolites, liver fat content and age attained a significantly higher AUC of 0.91 (p < 0.001). The AUCs of these metabolites remained highly significant in the independent validation cohorts involving 200 MAFLD patients and 90 controls. Conclusions Diagnostic models combining different metabolites according to BMI categories could raise the accuracy of identifying subclinical CAS. Trial registration The study protocol was approved by the local ethics committee and all the participants have provided written informed consent (Approval number: [2014] No. 112, registered at the Chinese Clinical Trial Registry, ChiCTR-ChiCTR2000034197) Graphical Abstrac

Pediatric colonoscopy in South China: a 12-year experience in a tertiary center.

OBJECTIVE: To investigate: 1) the demographics and clinical characteristics, 2) the findings, and 3) the safety and effectiveness in a cohort of Chinese pediatric patients undergoing colonoscopy. METHODS: The study participants were consecutive patients aged ≤14 years old that underwent their first colonoscopy in the endoscopy center at the First Affiliated Hospital, Sun Yat-sen University between Jan. 1, 2001 and Dec. 31, 2012. Demographic, clinical, endoscopic, and pathological findings were collected. RESULTS: The cohort consisted of 322 patients, including 218 boys (67.7%) and 104 girls (32.3%). The median age was 8.0 years old and ranged from 9 months to 14 years old. Hematochezia (48.8%) and abdominal pain/discomfort (41.3%) were the most common presentations preceding pediatric colonoscopy. The caecal intubation success rate was 96.3%. No serious complications occurred during the procedures. A total of 227 patients (70.5%) received a positive diagnosis under endoscopy, including 138 patients with polyps and 53 patients with inflammatory bowel disease (IBD). Among the patients with polyps, 71.0% were juvenile polyps. Comparisons between years 2001-2006 and 2007-2012 showed that the IBD detection rate increased significantly (4.6% vs. 22.4%, P<0.001), while the opposite occurred for the polyp detection rate (73.1% vs. 27.6%, P<0.001). CONCLUSION: Colonoscopy in pediatric patients is a safe and effective procedure. Polyps are the primary finding during colonoscopy. In South China there has been an increase in pediatric patients diagnosed with IBD over the past decade. However, a large epidemiological study is needed to confirm our findings

Comparisons of gender, age, and colonoscopic findings between the years 2001–2006 and 2007–2012.

<p>IQR^a: interquartile range; IBD^b: inflammatory bowel disease.</p

Changes on the detection rates of polyp and IBD over time.

<p>The detection rates of polyp and IBD in pediatric patients were analyzed year by year and compared over time (2001–2012).</p

Management protocol for this study.

<p>Children aged ≤14 years old undertaking their first diagnostic colonoscopy at the endoscopy center of the First Affiliated Hospital, Sun Yat-sen University between Jan. 1, 2001 and Dec. 31, 2012 were enrolled in the study.</p